We’ve created INOFEA from the desire to meet a critical need related to enzyme lack of stability and robustness: the possibility to provide enzymes with resistance to in vivo and process conditions, so that they could be fully deployed in the health industry.
Unlike other existing technologies, our innovative nanotechnology platform is capable of shielding sensitive enzymes and has positively demonstrated substantial benefits to customers in a number of health industry applications.
Anne Timm to the position as Chief Business Officer
We are pleased to announce the recent hiring of Anne Timm to the position as Chief Business Officer. Anne started on May 01, 2018 and comes to Inofea with 30 years of experience in Marketing and Sales in the Chemical and Biotech field. She holds a PhD degree in biology toxicology from University of Darmstadt, Germany.
Her background in both biomedical and business management is a truly valuable asset to our company.
Anne is responsible to further develop our market potential and building long-lasting relationships with existing and new acquired business partners.
Needless to say, we're thrilled to have somebody with Anne's track record working for us.
A warm welcome from Inofea, Anne!